Vericel Corp Ord (VCEL) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Vericel Corp Ord stock (VCEL) is currently trading at $31.44. Vericel Corp Ord PE ratio is 103.38. Vericel Corp Ord PS ratio (Price-to-Sales) is 6.10. Analyst consensus price target for VCEL is $55.43. WallStSmart rates VCEL as Underperform.
- VCEL PE ratio analysis and historical PE chart
- VCEL PS ratio (Price-to-Sales) history and trend
- VCEL intrinsic value — DCF, Graham Number, EPV models
- VCEL stock price prediction 2025 2026 2027 2028 2029 2030
- VCEL fair value vs current price
- VCEL insider transactions and insider buying
- Is VCEL undervalued or overvalued?
- Vericel Corp Ord financial analysis — revenue, earnings, cash flow
- VCEL Piotroski F-Score and Altman Z-Score
- VCEL analyst price target and Smart Rating
Vericel Corp Ord
📊 No data available
Try selecting a different time range
VCEL Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · Vericel Corp Ord (VCEL)
VCEL trades 192% above its Graham fair value of $11.85, indicating the stock may be overvalued at current levels.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
Vericel Corp Ord (VCEL) · 9 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in operating margin, revenue growth, institutional own.. Concerns around return on equity. Fundamentals are solid but monitor weak areas for improvement.
Vericel Corp Ord (VCEL) Key Strengths (3)
107.46% of shares held by major funds and institutions
Strong operational efficiency: $24 kept per $100 revenue
Strong revenue growth at 23.30% annually
Supporting Valuation Data
Vericel Corp Ord (VCEL) Areas to Watch (6)
Low profitability relative to shareholder equity
Premium valuation at 6.1x annual revenue
Premium pricing at 4.5x book value
Thin profit margins with limited profitability
Small-cap company with higher risk but more growth potential
Solid earnings growth at 18.90%
Supporting Valuation Data
Vericel Corp Ord (VCEL) Detailed Analysis Report
Overall Assessment
This company scores 50/100 in our Smart Analysis, earning a C- grade. Out of 9 metrics analyzed, 3 register as strengths (avg 8.7/10) while 6 fall into concern territory (avg 4.3/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Institutional Own., Operating Margin, Revenue Growth. Profitability is solid with Operating Margin at 24.10%. Growth metrics are encouraging with Revenue Growth at 23.30%.
The Bear Case
The primary concerns are Return on Equity, Price/Sales, Price/Book. Some valuation metrics including Price/Sales (6.10), Price/Book (4.50) suggest expensive pricing. Growth concerns include EPS Growth at 18.90%, which may limit upside. Profitability pressure is visible in Return on Equity at 5.11%, Profit Margin at 5.98%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 5.11% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 23.30% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a moderate-to-high risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Mixed fundamentals with both positives (Institutional Own., Operating Margin) and negatives (Return on Equity, Price/Sales). A cautious approach is warranted. Monitor for improvement in weak areas before increasing conviction.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
VCEL Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
VCEL's Price-to-Sales ratio of 6.10x sits near its historical average of 6.12x (43th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 7% below its historical high of 6.53x set in Mar 2026, and 6% above its historical low of 5.77x in Mar 2026.
WallStSmart Analysis Synopsis
Data-driven financial summary for Vericel Corp Ord (VCEL) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Vericel Corp Ord is a strong growth company balancing expansion with improving profitability. Revenue reached 276M with 23% growth year-over-year. Profit margins are thin at 6.0%, typical for companies in this phase that are reinvesting heavily in growth.
Key Findings
ROE of 511.0% means the company generates strong returns on shareholder equity. Above 20% is considered top-tier.
Generating 802,000 in free cash flow and 15M in operating cash flow. Earnings are translating into actual cash generation.
What to Watch Next
Margin expansion: can Vericel Corp Ord push profit margins above 15% as the business scales?
Growth sustainability: can Vericel Corp Ord maintain 23%+ revenue growth, or will competition slow it down?
Valuation compression risk at a P/E of 103.4x. Any growth miss could trigger a sharp correction.
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Vericel Corp Ord.
Bottom Line
Vericel Corp Ord offers an attractive blend of growth (23% revenue expansion) and improving fundamentals. The company is transitioning from pure growth to profitable growth, a critical inflection point. Watch for sustained margin expansion as the key signal.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Vericel Corp Ord(VCEL)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, and distributes cell therapies for the sports medicine and severe burn care markets in the United States. The company is headquartered in Cambridge, Massachusetts.